» Authors » Simone Ronsisvalle

Simone Ronsisvalle

Explore the profile of Simone Ronsisvalle including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 64
Citations 435
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Spampinato M, Carota G, Sferrazzo G, Fuochi V, Distefano A, Ronsisvalle S, et al.
Pharmaceutics . 2022 Dec; 14(12). PMID: 36559338
The growing interest in natural bioactive molecules, as an approach to many pathological contexts, is widely justified by the necessity to overcome the disadvantageous benefit-risk ratio related to traditional therapies....
12.
Ma O, Ronsisvalle S, Basile L, Xiang A, Tomasella C, Sipala F, et al.
Biomed Pharmacother . 2022 Dec; 158:114141. PMID: 36542987
Diabetic neuropathy (DN) is a long-term complication of diabetes mellitus, affecting different periphery nerve systems including sensory and motor neurons. Hyperglycemia is the major cause of DN with symptoms such...
13.
Genovese C, Garozzo A, DAngeli F, Malfa G, Bellia F, Tomasello B, et al.
Cells . 2022 May; 11(10). PMID: 35626733
Background: Breast cancer (BC) is the leading cause of death worldwide. The severity of BC strictly depends on the molecular subtype. The less aggressive hormone-positive subtype is treated with adjuvant...
14.
DAngeli F, Guadagni F, Genovese C, Nicolosi D, Salinaro A, Spampinato M, et al.
Antibiotics (Basel) . 2021 Nov; 10(11). PMID: 34827311
() and () are part of the human microbiome. However, they possess numerous virulence factors, which confer them the ability to cause both local and systemic infections. Candidiasis can involve...
15.
Carota G, Ronsisvalle S, Panarello F, Tibullo D, Nicolosi A, Volti G
J Clin Med . 2021 Jun; 10(11). PMID: 34070628
Although the epidemic caused by SARS-CoV-2 callings for international attention to develop new effective therapeutics, no specific protocol is yet available, leaving patients to rely on general and supportive therapies....
16.
DAngeli F, Malfa G, Garozzo A, Volti G, Genovese C, Stivala A, et al.
Antibiotics (Basel) . 2021 Feb; 10(2). PMID: 33557378
The difficulty to treat resistant strains-related hospital-acquired infections (HAIs) promoted the study of phytoextracts, known sources of bioactive molecules. Accordingly, in the present study, the pharmacological activities of (L.) pellicle...
17.
Ronsisvalle S, Panarello F, Di Mauro R, Bernardini R, Volti G, Cantarella G
Curr Pharm Des . 2020 Dec; 27(10):1323-1329. PMID: 33302855
Background: The evolution of the pandemic has burdened the national healthcare systems worldwide and at present, there is no preferred antiviral treatment for COVID-19. Recently, the SARS-Cov-2 protease structure was...
18.
Linciano P, Sorbi C, Comitato A, Lesniak A, Bujalska-Zadrozny M, Pawlowska A, et al.
ACS Chem Neurosci . 2020 Dec; 11(24):4111-4127. PMID: 33263393
Opioids are the gold standard drugs for the treatment of acute and chronic severe pain, although their serious side effects constitute a big limitation. In the search for new and...
19.
Ronsisvalle S, Panarello F, Spadaro A, Franchini S, Pappalardo M, Guccione S, et al.
Future Med Chem . 2020 Sep; 12(22):2001-2018. PMID: 32972243
Central and peripheral analgesia without adverse effects relies on the identification of μ-opioid agonists that are able to activate 'basal' antinociceptive pathways. Recently developed μ-selective benzomorphan agonists that are not...
20.
Spadaro A, Basile L, Pappalardo M, Bonaccorso C, Rao M, Ronsisvalle S, et al.
J Chem Inf Model . 2020 Aug; 60(10):5162-5171. PMID: 32818373
Functional antitumor vaccine constructs are the basis for active tumor immunotherapy, which is useful in the treatment of many types of cancers. MUC1 is one key glycoprotein for targeting and...